Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy
The development of ARAs represents one of the most important prognostic factors in pMN, being significantly associated with a reduced remission rate and a higher relapse rate after rituximab therapy. Alternative therapies with obinutuzumab or ofatumumab should be considered for these patients.
Authors
- Vesna Brglez (ORCID: https://orcid.org/0000-0002-3357-5017)
- Alessandra Vultaggio (ORCID: https://orcid.org/0000-0002-8775-9217)
- Barbara Seitz‐Polski (ORCID: https://orcid.org/0000-0002-8913-5969)
- Marion Crémoni (ORCID: https://orcid.org/0000-0002-5837-9469)
- Lorenzo Cosmi (ORCID: https://orcid.org/0000-0002-8150-8177)
- Maxime Teisseyre (ORCID: https://orcid.org/0000-0002-3601-0572)
- Andrea Matucci (ORCID: https://orcid.org/0000-0002-3499-992X)
- Tommaso Mazzierli
- Kévin Zorzi
- Matteo Accinno
- Leonardo Caroti (ORCID: https://orcid.org/0000-0002-0612-3517)
- Cinzia Finocchi (ORCID: https://orcid.org/0000-0003-4385-1203)
- Céline Fernandez
- Vincent Esnault (ORCID: https://orcid.org/0000-0002-7418-5672)
- Marco Allinovi (ORCID: https://orcid.org/0000-0001-9949-3543)
- Calogero Lino Cirami (ORCID: https://orcid.org/0000-0002-3776-4691)
- Giulia Antognoli (ORCID: https://orcid.org/0000-0002-9676-7024)
- Daniela Lazzarini
- Micaela Anna Casiraghi
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Institut de Recherche sur le Cancer et le Vieillissement de Nice (FR)
- University of Florence (IT)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1016/j.ekir.2025.04.059
- Citations
- 10
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 14.31